Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
8 June 2024

Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics

Authors: Krithika Rajagopalan https://orcid.org/0000-0002-4878-0822 [email protected], Nazia Rashid https://orcid.org/0000-0002-4227-1234, Daksha Gopal, and Dilesh DoshiAuthor Info & Affiliations
Volume 13, Number 7
https://doi.org/10.57264/cer-2024-0038
PDFFormats

Abstract

Aim: Real-world healthcare resource use (HCRU) burden among patients with Parkinson's disease psychosis (PDP) treated with pimavanserin (PIM) versus other atypical antipsychotics (other-AAPs) including quetiapine (QUE) in long term care (LTC) and nursing home (NH) settings are lacking. This analysis examines HCRU differences among residents in LTC/NH settings who initiate PIM versus QUE or other-AAPs. Methods: A retrospective analysis of LTC/NH residents with PDP from the 100% Medicare claims between 1 April 2015 and 31 December 2021 was conducted. Treatment-naive residents who initiated ≥6 months continuous monotherapy with PIM or QUE or other-AAPs between 04/01/16 and 06/30/2021 were propensity score matched (PSM) 1:1 using 31 variables (age, sex, race, region and 27 Elixhauser comorbidity characteristics). Post-index (i.e., 6 months) HCRU outcomes included: proportion of residents with ≥1 all-cause inpatient (IP) hospitalizations and emergency room (ER) visits. HCRU differences were assessed via log binomial regression and reported as relative risk ratios (RR) and 95% confidence intervals after controlling for dementia, insomnia and index year. Results: From a total of PIM (n = 1827), QUE (n = 7770) or other-AAPs (n = 9557), 1:1 matched sample (n = 1827) in each cohort were selected. All-cause IP hospitalizations (PIM [29.8%]) versus QUE [36.7%]) and ER visits (PIM [47.3%] versus QUE [55.8%]), respectively, were significantly lower for PIM. PIM versus QUE cohort also had significantly lower RR for all-cause IP hospitalizations and ER visits, respectively, (IP hospitalizations RR: 0.82 [0.75. 0.9]; ER visits RR: 0.85 [0.8. 0.9]). PIM versus other-AAPs also had lower likelihood of HCRU outcomes. Conclusion: In this analysis, LTC/NH residents on PIM monotherapy (versus QUE) had a lower likelihood of all-cause hospitalizations (18%) and ER (15%) visits. In this setting, PIM also had lower likelihood of all-cause HCRU versus other-AAPs.

Formats available

You can view the full content in the following formats:

View PDFView Full Text

Supplementary Material

File (supplementary material.docx)

References

Papers of special note have been highlighted as: • of interest
1.
Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348(14), 1356–1364 (2003).
PubMed
Google Scholar
3.
Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 28(3), 311–318 (2013).
PubMed
Google Scholar
4.
Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 8(3), 193–197 (2002).
PubMed
Google Scholar
5.
Witjas T, Kaphan E, Azulay JP et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59(3), 408–413 (2002).
PubMed
Google Scholar
6.
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60(3), 387–392 (2003).
PubMed
Google Scholar
• This prospective study found that more than three quarters of a population-based and representative cohort of patients with Parkinson's disease developed dementia during the 8-year study period. Early hallucinations and akinetic-dominant Parkinson's disease were associated with an increased risk of dementia.
7.
Ravina B, Marder K, Fernandez HH et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov. Disord. 22(8), 1061–1068 (2007).
PubMed
Google Scholar
8.
Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov. Disord. 26(3), 399–406 (2011).
PubMed
Google Scholar
9.
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23(6), 837–844 (2008).
PubMed
Google Scholar
10.
Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of “benign hallucinations” in Parkinson disease. Arch. Neurol. 63(5), 713–716 (2006).
PubMed
Google Scholar
11.
Cook K, Suresh R, Lou KJ et al. Parkinson's Disease Psychosis – Patterns of Care and Treatment in the EU-5 from Neurologists' Perspective. Eur. Neurol. Rev. 12(2), 92–99 (2017).
Google Scholar
• In this survey, patient chart reviews were developed and targeted to medical practitioner specialists in the five European union nations. Across these countries, the most frequently reported interventions used to manage symptoms of Parkinson's disease psychosis (PDP) were antipsychotics (29%) and PD medications adjustment (28%). The pharmacological agent for managing symptoms of PDP regardless of line of therapy was quetiapine (54%), followed by anti-dementia agents (38%), other non-antipsychotic/non-anti-dementia agents (29%) and clozapine (27%).
12.
Fénelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J. Neurol. Sci. 289(1–2), 12–17 (2010).
PubMed
Google Scholar
• This cross-sectional study demonstrates lifetime prevalence of psychotic symptoms over 50%, and the more prevalent symptoms are ‘minor’ phenomena and visual hallucinations. The study also concludes that main risk factor for hallucinations is dementia.
13.
Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden. Am. J. Manag. Care 23(Suppl. 5), S83–S92 (2017).
PubMed
Google Scholar
14.
Safarpour D, Thibault DP, DeSanto CL et al. Nursing home and end-of-life care in Parkinson disease. Neurology 85(5), 413–419 (2015).
PubMed
Google Scholar
15.
Hermanowicz N, Edwards K. Parkinson's disease psychosis: symptoms, management, and economic burden. Am. J. Manag. Care 21(Suppl. 10), S199–S206 (2015).
PubMed
Google Scholar
• In this review article, authors talk about Parkinson's disease psychosis as a costly and debilitating condition that often develops several years after the initial diagnosis of Parkinson's disease (PD). Patients with PDP experience higher healthcare expenditures, particularly in long-term care, skilled nursing facilities and inpatient settings, compared with patients with PD without psychosis.
16.
Seppi K, Ray Chaudhuri K, Coelho M et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review [published correction appears in Mov. Disord. 34(5), 765 (2019)]. Mov. Disord. 34(2), 180–198 (2019).
PubMed
Google Scholar
17.
Rajagopalan K, Rashid N, Kumar S, Doshi D. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics. J. Med. Econ. 26(1), 34–42 (2023).
PubMed
Google Scholar
18.
Alipour-Haris G, Armstrong MJ, Okun M, Brown JD. Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among medicare beneficiaries with Parkinson's disease psychosis. Mov. Disord. Clin. Pract. 10(3), 406–414 (2023).
PubMed
Google Scholar
• In this retrospective cohort study, hospitalization and mortality risk for antipsychotic-naïve individuals with PD who were receiving new prescriptions for pimavanserin, or quetiapine were compared. Pimavanserin use was associated with 30% lower hospitalization rates versus quetiapine (44%) during a 1-year follow-up period.
19.
Rajagopalan K, Rashid N, Doshi D. Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries. J. Med. Econ. 26(1), 769–776 (2023).
PubMed
Google Scholar
20.
Sewell DD, Jeste DV, Atkinson JH et al. HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group. Am. J. Psych. 151(2), 237–242 (1994).
PubMed
Google Scholar
21.
Beckett MK, Collins RL, Burnam MA et al. Mental Health and Substance Abuse Issues Among People with HIV Lessons from HCSUS. https://www.rand.org/pubs/research_briefs/RB9300.html (2007).
Google Scholar
22.
Substance Abuse and Mental Health Services Administration. Co-occurring disorders and other health conditions (2022). https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/co-occurring-disorders
Google Scholar
23.
Sterling S, Chi F, Hinman A. Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions. Alcohol Res. Health 33(4), 338–349 (2011).
PubMed
Google Scholar
24.
Rajagopalan K, Kumar S, Rashid N, Doshi D. Incidence of all-cause falls and fractures among nursing facility patients treated with pimavanserin versus other atypical antipsychotics with Parkinson's disease psychosis: analysis of Medicare beneficiaries. Sr Care Pharm. 37(11), 573–597 (2022).
PubMed
Google Scholar
25.
Layton JB, Forns J, Turner ME et al. Falls and fractures in patients with Parkinson's Disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes 9(1), 9–22 (2022).
PubMed
Google Scholar
• This study focused on a cohort of patients with Parkinson's disease-related psychosis and aimed to evaluate the risk of falls and fractures associated with the use of pimavanserin compared with other antipsychotics. The results indicate that there is no evidence suggesting an increased risk of falls or fractures with pimavanserin use in PDP patients, sensitivity analyses even suggest a decreased risk.
26.
Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu. Rev. Public Health 20, 125–144 (1999).
PubMed
Google Scholar
|